Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer

December 24, 2020

Dolly Sharma, PhD

, Jeffrey Wojtynek, PharmD

Jeffrey Wojtynek, PharmD

, Kathleen M. Fox, PhD

Kathleen M. Fox, PhD

, Chelsea Cooper, PharmD

Chelsea Cooper, PharmD

, Igoni Dokubo, MD

Igoni Dokubo, MD

Evidence-Based Oncology, February 2021, Volume 27, Issue 2

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.

Download Issue : February 2021